Healthcare / Medical Instruments & SuppliesShanghai
$16.48
+0.04 (+0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $60.0M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.3B
P/E
32.3x
↑EV/EBITDA
24.9x
↑ROE
8.2%
↑Gross Margin
50.2%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.3%
FCF CAGR
-13.3%
FCF margin
18.8%
FCF / Net income
1.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $806.9M · net income $145.9M · FCF $151.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $806.9M | $806.9M | $567.3M | $690.1M | $382.0M |
| Net Income | $145.9M | $145.9M | $70.9M | $194.5M | $59.2M |
| EBITDA | $187.4M | $187.4M | $90.3M | $238.8M | $81.0M |
| EPS | 0.46 | 0.46 | 0.22 | 0.61 | 0.18 |
| Gross Margin | 50.2% | 50.2% | 45.3% | 49.9% | 43.6% |
| Operating Margin | 22.7% | 22.7% | 10.7% | 27.8% | 16.9% |
| Net Margin | 18.1% | 18.1% | 12.5% | 28.2% | 15.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 4.12 | 4.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $151.9M | $151.9M | $60.0M | $-48.0M | $232.9M |
| Returns | |||||
| ROE | 8.2% | 8.2% | 4.2% | 11.5% | 3.9% |
| Valuation | |||||
| P/E | 32.31 | 32.31 | 48.40 | 31.54 | 72.95 |
| EV/EBITDA | 24.91 | 24.91 | 31.04 | 22.49 | 35.84 |
| P/B | 2.95 | 2.95 | 2.03 | 3.61 | 2.85 |
| Growth & Yield | |||||
| Revenue Growth | 42.2% | 42.2% | -17.8% | 80.7% | — |
| EPS Growth | 107.0% | 107.0% | -63.4% | 228.3% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
47.2%
EPS terminal req.
$1.46
Spread vs growth
59.8%
5Y implied EPS CAGR
31.0%
EPS terminal req.
$1.77
Spread vs growth
76.0%
10Y implied EPS CAGR
20.0%
EPS terminal req.
$2.85
Spread vs growth
87.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.5%
Start / end P/E
60.0x → 35.9x
EPS bridge
0.22 → 0.46
Residual
-42.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.